Type-2 inflammatory mediators as targets for precision medicine in children

Riccardo Castagnoli, Amelia Licari, Sara Manti, Elena Chiappini, Gian Luigi Marseglia

Research output: Contribution to journalArticlepeer-review


The prevalence, heterogeneity, and severity of type 2 inflammatory diseases, including asthma and atopic dermatitis, continue to rise, especially in children and adolescents. Type 2 inflammation is mediated by both innate and adaptive immune cells and sustained by a specific subset of cytokines, such as interleukin (IL)-4, IL-5,IL-13, and IgE. IL-4 and IL-13 are considered signature type 2 cytokines, as they both have a pivotal role in many of the pathobiologic changes featured in asthma and atopic dermatitis. Several biologics targeting IL-4, IL-5, and IL-13, as well as IgE, have been proposed to treat severe allergic disease in the pediatric population with promising results. A better definition of type 2 inflammatory pathways is essential to implement targeted therapeutic strategies.

Original languageEnglish
Pages (from-to)17-19
Number of pages3
JournalPediatric Allergy and Immunology
Issue numberS26
Publication statusPublished - Nov 2020


  • asthma
  • atopic dermatitis
  • biologics
  • children
  • type 2 inflammation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Type-2 inflammatory mediators as targets for precision medicine in children'. Together they form a unique fingerprint.

Cite this